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Class switch recombination (CSR) is a DNA recombi-
nation reaction that diversifies the effector compo-
nent of antibody responses. CSR is initiated by
activation-induced cytidine deaminase (AID), which
targets transcriptionally active immunoglobulin
heavy chain (Igh) switch donor and acceptor DNA.
The 30 Igh super-enhancer, 30 regulatory region
(30RR), is essential for acceptor region transcription,
but how this function is regulated is unknown. Here,
we identify the chromatin reader ZMYND8 as an
essential regulator of the 30RR. In B cells, ZMYND8
binds promoters and super-enhancers, including
the Ighenhancers. ZMYND8controls the 30RRactivity
by modulating the enhancer transcriptional status. In
its absence, there is increased 30RR polymerase
loading and decreased acceptor region transcription
and CSR. In addition to CSR, ZMYND8 deficiency im-
pairs somatic hypermutation (SHM) of Igh, which is
also dependent on the 30RR. Thus, ZMYND8 controls
Igh diversification in mature B lymphocytes by regu-
lating the activity of the 30 Igh super-enhancer.
INTRODUCTION
Class switch recombination (CSR) is a B-lymphocyte-specific
somatic recombination reaction that replaces the Cm constant
region of the immunoglobulin heavy chain (Igh) locus with one
of the downstream constant genes (Chaudhuri and Alt, 2004;
Pavri and Nussenzweig, 2011). As a consequence, B cells switch636 Molecular Cell 72, 636–649, November 15, 2018 ª 2018 The Aut
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M (IgM) class to IgG, IgE, or IgA, which harbor the same antigen
specificity but a different effector function. This process is
essential for the establishment of an effective immune response
as evidenced by primary human immunodeficiency syndromes
that are associated with defects in CSR (Durandy et al., 2013).
The Igh locus spans over 250 kb, and comprises a rearranged
variable, diversity, and joining (VDJ) exon, encoding the variable
portion of the antibody molecule, followed by exons encoding
constant (C) regions (Cm, Cg3, Cg1, Cg2b, Cg2a, Cε, and Ca in
mice), each preceded by highly repetitive stretches of DNA,
known as switch (S) regions. The Igh locus contains two impor-
tant transcriptional enhancers, Em and 30 regulatory region (30RR)
that are essential for B cell development and function. In addition
to supporting Igh expression, Em is required for efficient V(D)J
recombination and early B cell development (Banerji et al.,
1983; Gillies et al., 1983; Marquet et al., 2014; Perlot et al.,
2005). The 30RR is essential for late B cell differentiation, when
it regulates antibody gene diversification by CSR and somatic
hypermutation (SHM) inmature B cells (Cogne´ et al., 1994;Manis
et al., 1998; Pinaud et al., 2001; Rouaud et al., 2013; Saintamand
et al., 2015a; Vincent-Fabert et al., 2010).
CSR is mediated by activation-induced deaminase (AID),
which targets cytosine residues within the S regions of activated
B cells (Muramatsu et al., 2000; Revy et al., 2000). The lesions
induced by AID initiate a cascade of enzymatic reactions result-
ing in the formation of DNA double-strand breaks (DSBs) (Bo-
boila et al., 2012). Paired breaks at donor and acceptor S regions
are then repaired by components of the nonhomologous end-
joining (NHEJ) pathway that includes Ku70/80, DNA ligase IV,
53BP1, and its downstream interactor Rif1, thus resulting in
deletion of the intervening sequence and expression of the newly
switched heavy chain (Boboila et al., 2012; Chapman et al., 2013;
Di Virgilio et al., 2013; Escribano-Dı´az et al., 2013).hors. Published by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
AID targeting is dependent on transcription across the S re-
gions (germline transcription [GLT]), which exposes single-
stranded DNA that is the substrate for this enzyme (Chaudhuri
et al., 2003; Dickerson et al., 2003; Ramiro et al., 2003). GLT is
initiated at a promoter coupled with an I (intervening) exon
located upstream of each S region and terminates downstream
of the corresponding CH gene (Gauchat et al., 1990; Lebman
et al., 1990; Lennon and Perry, 1985; Lutzker and Alt, 1988; Rad-
cliffe et al., 1990; Rothman et al., 1990a, 1990b). Whereas tran-
scription of the donor Sm region is constitutive in naive B cells,
GLT of acceptor regions is induced in a cytokine-dependent
manner, which targets CSR to different isotypes (Berton et al.,
1989; Collins and Dunnick, 1993; Esser and Radbruch, 1989;
Gauchat et al., 1990; Lebman et al., 1990; Lutzker et al., 1988;
Rothman et al., 1988; Severinson et al., 1990; Shockett and
Stavnezer, 1991; Stavnezer et al., 1985, 1988). The 30RR acts
as a major regulator of this process (Birshtein, 2014; Pinaud
et al., 2011). The 30RR is located downstream of Ca and contains
four lymphoid-specific transcriptional enhancers (DNase 1 hy-
persensitive sites hs3a, hs1,2, hs3b, and hs4) in mice (Giannini
et al., 1993; Lieberson et al., 1991; Madisen and Groudine,
1994; Matthias and Baltimore, 1993; Michaelson et al., 1995;
Pettersson et al., 1990). hs1,2 is at the center of a 25-kb palin-
drome delimited by two inverted copies of the hs3 enhancers
(hs3a and hs3b), with the distal hs4 module lying outside and
downstream of the palindrome (Birshtein, 2014; Pinaud et al.,
2011). Both hs core enhancers and surrounding sequences
have proven to be crucial to promote CSR by regulating GLT
and accessibility of the S regions (Cogne´ et al., 1994; Garot
et al., 2016; Le Noir et al., 2017; Manis et al., 1998; Pinaud
et al., 2001; Saintamand et al., 2015b; Vincent-Fabert et al.,
2010). However, the mechanism by which the activity of the
30RR is regulated has yet to be defined precisely.
Here, we identified zinc finger MYND-type containing
8 (ZMYND8) protein as a factor required for physiological levels
of CSR. ZMYND8 is dispensable for repair of CSR breaks but
acts upstream DSB formation by controlling 30RR activity.
RESULTS
The Chromatin Reader ZMYND8 Is Required for CSR
To investigate the regulation of antibody diversification by CSR,
we determined the protein interactome of the CSR and DSB
repair factor Rif1 in switching B lymphocytes. To this end, we
applied the proteomics-based technique isotopic differentiation
of interactions as random or targeted (I-DIRT) (Tackett et al.,
2005) to B lymphocytes stimulated to undergo CSR (Figure S1).
We employed primary cultures of splenocytes isolated from
Rif1FH/FH mice (Cornacchia et al., 2012), which express physio-
logical levels of a knockin 13Flag-23hemagglutinin (HA)-tagged
version of Rif1 that supports normal levels of CSR (Figures
S1A–S1C). As expected, the two top hits were the Rif1 bait
and its phospho-dependent interactor 53BP1 (Figures S1D
and S1E). Several proteins exhibited I-DIRT ratios that were mul-
tiple SDs above the mean, suggesting that they are specifically
associated with Rif1. Among these were a number of transcrip-
tional regulators, including MGA, Zfp592, BACH2, TCEB1, and
ZMYND8 (Figures S1D and S1E).To identify bona fide CSR factors, candidates with high I-DIRT
ratio were assessed by somatic targeting using CRISPR-Cas9 in
the B cell lymphoma line CH12 (Nakamura et al., 1996; Figures
S1F and S1G). Upon cytokine stimulation, CH12 cells express
AID and undergo class switching to IgA with high efficiency.
Moreover, ablation of factors known to be essential for CSR,
such as AID, 53BP1, and Rif1, reduces CSR in CH12 cells (Fig-
ure S1G). Among the candidates tested, ZMYND8 showed the
greatest impairment in CSR (Figures 1A, 1B, and S1G). In agree-
ment with the targeting results in bulk cultures, ZMYND8-defi-
cient CH12 clones exhibited reduced levels of CSR compared
to controls (Figure 1C). Furthermore, complementation of
Zmynd8/ CH12 cell lines with full-length ZMYND8 fully
rescued CSR, thus confirming that the defect is specifically
caused by ZMYND8 deficiency (Figure 1D).
To validate the I-DIRT result and confirm that ZMYND8 is a
Rif1 interactor, we performed reciprocal co-immunoprecipita-
tion experiments in primary B cells. We found that ZMYND8
was efficiently co-immunoprecipitated with Rif1 and vice versa
(Figures S1H and S1I). Ionizing irradiation (IR)-induced DNA
damage resulted in the association between Rif1 and 53BP1 in
a manner dependent on the DSB repair kinase ataxia-telangiec-
tasia mutated (ATM) (Figure S1H; Di Virgilio et al., 2013). In
contrast, ZMYND8 co-immunoprecipitated with Rif1 irrespective
of DNA damage or ATM activity (Figures S1H and S1I). We
concluded that ZMYND8 interacts with Rif1 in a DNA-damage-
independent manner.
To confirm the findings obtained in CH12 cells, we specifically
deleted ZMYND8 in B cells by combining a Zmynd8F conditional
allele withCd19-Cre, which drives Cre expression at early stages
of B cell differentiation (Rickert et al., 1997; Figure S2A). B cells
from Zmynd8F/FCd19Cre/+ mice developed normally (Figures
S2B and S2C), thus indicating that ZMYND8 is dispensable for
V(D)J recombination and B cell development. To assess whether
ZMYND8 is required for CSR in primary B cells, we activated
splenocytes with appropriate stimuli to induce switching to
IgG1, IgG2b, and IgG3. ZMYND8 protein was readily detectable
in resting B cells, and expression levels did not change following
activation (Figure S2D). Mature ZMYND8-deficient B cells
showed a severe defect in CSR to all tested isotypes (Figures
2A–2C). To assess whether the defect we observed in primary
B cell cultures reflected a reduced capability to mount a proper
immune response in vivo, we immunized Cd19Cre/+ and
Zmynd8F/FCd19Cre/+ mice with the T-cell-dependent antigen
4-Hydroxy-3-nitrophenylacetyl hapten conjugated to Chicken
Gamma Globulin (NP-CGG). The generation of NP-specific
IgG1 antibodies was reduced nearly 5-fold in ZMYND8-deficient
mice compared to control group (Figure 2D). We conclude that
ZMYND8 is essential for physiologic levels of CSR in primary B
lymphocytes.
ZMYND8 Is Dispensable for DSB Repair
CSR is dependent on the detection, signaling, and repair of
AID-induced DSBs (Boboila et al., 2012; Pavri and Nussenz-
weig, 2011). To determine whether loss of ZMYND8 alters
any of these processes, we produced and analyzed
ZMYND8-deficient mouse embryonic fibroblasts (MEFs) cell
lines (Figures S3A and S3B). DSB signaling was measured byMolecular Cell 72, 636–649, November 15, 2018 637
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Figure 1. ZMYND8 Ablation in CH12 Impairs CSR
(A) Scheme of Zmynd8 genomic locus and location of guide RNAs (gRNAs) used in this study.
(B) (Left top) Representative flow cytometry plots measuring CSR to IgA in activated Cas9/gZmynd8-nucleofected CH12 cells. (Left bottom)Western blot analysis
of whole-cell extracts from nucleofected CH12 cultures is shown. (Right) Summary dot plot indicating CSR as a percentage of the control (Ctrl) value within the
same experiment is shown. The graph summarizes three independent experiments. Aicda, AID-encoding gene.
(C) Graph depicting CSR to IgA in activatedCH12 clonal derivatives. Each cell line was normalized to themean value of the control clones, whichwas set to 100%.
Graph is representative of at least two independent experiments.
(D) (Left) Summary dot plot for four independent experiments measuring CSR to IgA 48 hr after activation of two Zmynd8/ CH12 cell lines (KO1 and KO2)
reconstituted with either empty vector (EV) or full-length ZMYND8 (top legend). CSR is expressed as a percentage of the uninfected WT within the same
experiment. (Right) Representative WB analysis of the CH12 cell lines is shown.
Significance in (B) and (C) was calculated with the Mann-Whitney U test. Error bars in (D) represent SD. *p% 0.05. See also Figure S1.assaying for formation of IR-induced foci (IRIF) of gH2AX,
53BP1, and Rif1. In all cases, formation of DNA damage foci
was normal in ZMYND8-deficient cell lines (Figure S3C).
Thus, ZMYND8 is not required for DSB detection and early
IR-induced signaling in this model system.
In addition, Zmynd8/ MEFs and Zmynd8/ CH12 cell lines
showed no measurable defect in survival after IR (Figures
S4A–S4C). Given reports that implicated ZMYND8 in homolo-
gous recombination (HR)-dependent repair of DSBs within tran-
scriptionally active loci (Gong et al., 2015, 2017; Kloet et al.,
2015; Spruijt et al., 2016; Xia et al., 2017), we assessed cell sur-638 Molecular Cell 72, 636–649, November 15, 2018vival and genomic instability in response to treatment with PARP
inhibitor (PARPi), which promotes DNA-replication-associated
damage that is physiologically repaired by HR. ZMYND8-defi-
cient MEFs displayed no increase in sensitivity to PARPi (Figures
S4D and S4E). Furthermore, DNA end protection from resection
and repair of CRISPR-Cas9-induced DSBs were normal in
Zmynd8/ CH12 cells (Figures S4F and S4G). Altogether, these
findings indicate that ZMYND8 is dispensable for DSB signaling
and repair in MEFs and CH12 cells.
To determine whether ZMYND8 contributes to repair of
AID-induced breaks, we analyzed residual Sm-Sg1 junctions
A B C
D
Figure 2. ZMYND8 Is Required for CSR In Vivo
(A–C) (Top) Representative flow cytometry plots measuring CSR to IgG1 (A), IgG2b (B), and IgG3 (C) in activated splenocytes. (Bottom) Summary dot plot for at
least 5 mice per time point per genotype is shown.
(D) NP-specific IgM and IgG1 antibody titers in serum collected before (day 0) and at day 7 and 20 after immunization with NP-CGG. NP-IgG1 antibodies were
undetectable at day 0.
Significance in (A)–(D) was calculated with the Mann-Whitney U test. Error bars in (A)–(D) represent SD. *p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001. See
also Figure S2.cloned from Zmynd8F/FCd19Cre/+ B cells stimulated with lipo-
polysaccharide (LPS) and interleukin-4 (IL-4). We found that
the frequency and length of microhomology at the junctions
were similar in Cd19Cre/+ and Zmynd8F/FCd19Cre/+ mice, thus
indicating that ZMYND8 deficiency does not bias the end-
joining repair of AID-induced Igh breaks toward the use of mi-
crohomology (Table S1). We concluded that ZMYND8 does
not influence the choice between NHEJ and alternative end-
joining (A-EJ) of S regions DSBs.ZMYND8 Promotes Germline Transcription of Acceptor
S Regions
The level of CSR in activated B cells is directly dependent on the
level of AID expression (Dorsett et al., 2008; Takizawa et al.,
2008; Teng et al., 2008). To determine whether decreased CSR
in Zmynd8F/FCd19Cre/+ splenocytes is due to altered AID expres-
sion, we measured AID mRNA by qPCR assays. AID expression
in ZMYND8-deficient splenocytes was indistinguishable from
controls (Figures 3A–3C). Moreover, a general survey of theMolecular Cell 72, 636–649, November 15, 2018 639
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Figure 3. ZMYND8 Deficiency Causes Defective Germline Transcription of Acceptor S Regions
qPCR analysis for Aicda mRNA, Igm, and Igg1 (A), Igg2b (B), and Igg3 (C) GLT levels in B cells activated to undergo CSR to the corresponding isotypes. The
schematic representations indicate the location of primers employed to analyze pre- and post-spliced germline transcripts. One Cd19Cre/+ mouse within each
experiment was assigned an arbitrary value of 1 (error bars represent SD). Significance was calculated with the Mann-Whitney U test. **p% 0.01, ***p% 0.001.
See also Figure S5.transcriptome of Zmynd8/ and control CH12 cell lines by RNA
sequencing (RNA-seq) (Figures S5A and S5B; Tables S2 and S3)
showed no downregulation of the expression of known CSR fac-640 Molecular Cell 72, 636–649, November 15, 2018tors (Figure S5C). We concluded that ZMYND8 deletion does not
alter CSR by interfering with the expression of AID or other
known essential regulators of CSR.
A B
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Figure 4. ZMYND8 Binds Promoters and Super-Enhancers in B Cells
(A) Genomic distribution of ZMYND8 ChIP-seq peaks in CH12 cells.
(B) Venn diagram of the overlap between ZMYND8 peaks and B cells super-enhancers. SE, super-enhancer.
(C) ZMYND8 occupancy at the Igh locus in WT and Zmynd8/ CH12 cell lines (KO1 and KO2). A schematic representation of the murine Igh locus showing
location of enhancers (in gray) and S regions (in black) is represented below.
Data in (A)–(C) are representative of two independent experiments.In addition to AID expression, CSR is dependent on normal
cell cycle progression. To determine whether ZMYND8 defi-
ciency is required for cell division in B cells, we analyzed
the proliferation of activated Zmynd8F/FCd19Cre/+ splenocytes
by cell tracking dye dilution. The proliferation profile of
ZMYND8-deficient B cells was indistinguishable from their
wild-type (WT) counterpart at all time points after activation (Fig-
ures S6A–S6C), whereas CSR levels were reduced irrespective
of the cell cycle division stage (Figure S6D). Furthermore,
Cd19Cre/+ and Zmynd8F/FCd19Cre/+ splenocytes exhibited
similar growth curves following activation (Figure S6E). These
findings indicate that ZMYND8 deficiency does not alter cell
proliferation in B cells.
AID targeting is dependent on noncoding transcription (GLT)
across the S regions (Chaudhuri and Alt, 2004). To examine the
possibility that ZMYND8 promotes S region transcription, we
measured GLT levels by qPCR at both donor (Sm) and acceptor
switch regions in ZMYND8-deficient splenocytes stimulated to
undergo CSR to different isotypes. Sm GLT was not affected
by ZMYND8 depletion irrespective of the stimulation conditions
(Figures 3A–3C), and we did not detect any significant decrease
in the frequency of AID-induced mutations at 50 Sm in ZMYND8-
deficient splenocytes (Figures S6F and S6G). In contrast, both
pre- and post-spliced acceptor GLTs were reduced in
Zmynd8F/FCd19Cre/+ cells (Figures 3A–3C), indicating the
ZMYND8 deficiency specifically interferes with the induction ofacceptor S region GLT. We next employed global nuclear run-
on sequencing (GRO-seq) (Core et al., 2008) to visualize nascent
RNA transcription at the Igh locus of B cells under stimulating
conditions that induce GLTm and ε and CSR to IgG1 and IgE (Fig-
ures S5D and S5E). In agreement with the GLT qPCR results,
ZMYND8-deficient cells exhibited lower levels of nascent RNA
at Sg1 and Sε, whereas transcription at donor Smwas unaffected
(Figures S5D and S5E). We concluded that ZMYND8 is required
to promote transcription of S acceptor regions and that the CSR
defect of ZMYND8-deficient B cells is due to inefficient accessi-
bility of these regions.
ZMYND8 Binds the Igh Enhancers and Represses
Transcription at 30RR
ZMYND8 is a histone mark reader that associates with pro-
moters and enhancers in several cell types and mediates either
transcriptional activation or, more frequently, repression (Adhik-
ary et al., 2016; Basu et al., 2017a, 2017b; Li et al., 2016; Malo-
vannaya et al., 2011; Poleshko et al., 2010; Savitsky et al., 2016;
Shen et al., 2016; Spruijt et al., 2016; Zeng et al., 2010). To
examine the mechanism responsible for defective germline Igh
transcription in Zmynd8/ B cells, we monitored ZMYND8 as-
sociation with chromatin in CH12 by chromatin immunoprecipi-
tation coupled with high-throughput sequencing (ChIP-seq). The
vast majority of ZMYND8 peaks colocalized with promoters and
distal intergenic regions (Figure 4A). To specifically assessMolecular Cell 72, 636–649, November 15, 2018 641
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whether ZMYND8 binds to super-enhancers in B cells, we
defined the pool of B cell super-enhancers (Qian et al.,
2014) that overlapped with ZMYND8 peaks. Remarkably,
ZMYND8 bound to nearly all of these regulatory elements (Fig-
ure 4B). Altogether, these findings indicate that ZMYND8 prefer-
entially associates with promoters and super-enhancers in
B cells.
The Igh locus contains two enhancer elements, Em and 30RR,
that are located at 50 of Sm and 30 of Ca, respectively (Birshtein,
2014; Perlot and Alt, 2008). The 30RR is a prototypical super-
enhancer (Pinaud et al., 2011; Whyte et al., 2013), which is
required for GLT induction and CSR in mature B lymphocytes
and, to a lesser extent, in CH12 cells (Issaoui et al., 2018; Kim
et al., 2016). As expected from the genome-wide distribution
(Figures 4A and 4B), ZMYND8 associates with the Igh locus in
activated CH12 and B cells and it binds the 50 Em and 30RR en-
hancers (Figures 4C and 5A).
Loss of ZMYND8 results in enhancer overactivation as seen
by increased enhancer RNA (eRNA) transcription (Shen et al.,
2016). To determine whether ZMYND8 occupancy at Igh en-
hancers alters their activity, we monitored RNA polymerase II
(Pol II) occupancy at the Igh locus in ZMYND8-deficient cells
by ChIP-seq. Pol II loading was significantly increased at the
30RR core enhancers hs1,2 and hs3b in ZMYND8-deficient
splenocytes and CH12 cells (Figures 5A, 5B, S7A, and S7B).
In contrast, no significant increase above controls was
observed in Rif1/ cells (Figures S7A and S7B). In agreement
with increased Pol II loading, transcription of hs1,2 and hs3b
eRNAs was increased in the absence of ZMYND8 both at the
nascent (GRO-seq analysis; Figure S5D) and steady-state
levels (Figures 5C and 5D). These findings suggest that
ZMYND8 modulates 30RR function by suppressing its transcrip-
tional activity.
To determine whether ZMYND8 controls the transcriptional
status of B cell super-enhancers other than the Ighs, we
analyzed the transcription profiles of ZMYND8-bound super-
enhancers (Figure 4B) in the WT versus Zmynd8-KO cells. In
total, 130 out of the 982 ZMYND8-occupied B cell super-
enhancers were differentially expressed based on RNA-seq
(Figure 5E; Table S4; log2FoldChange > 1; red and green
dots). Of those, 90 displayed increased Pol II loading in
the Zmynd8-KO cells when compared to WT (Figure 5E;
log2FoldChange > 0). Seven super-enhancers exhibited theFigure 5. ZMYND8 Represses 30RR Enhancer Transcription
(A) (Top) ZMYND8 and Pol II loading at the Igh locus in splenocytes stimulated f
encompassing Em and 30RR enhancers.
(B) Pol II loading quantification at Igh enhancers. Graph summarizes ChIP-seq d
calculated with Welch 2 sample unpaired t test.
(C) qPCR analysis for hs1,2 and hs3b eRNA levels in B cells 48 hr after stimulat
the 50 (50 hs3b) and 30 (30 hs3b) regions of hs3bwere employed. The data summariz
each experiment was assigned an arbitrary value of 1.0. Significance was calcul
(D) (Left) Heatmap showing Igh 30RR enhancers differential transcript expression
two independent Zmynd8/CH12 clones (KO1 and KO2). Expression counts are
are shown. (Right) Bar graphs depicting relative transcript levels at hs4, hs1,2, hs
test and corrected for multiple testing with the Benjamini-Hochberg method.
(E) (Left) Graph depicting ZMYND8-bound B cell super-enhancers that are differ
DE SE, differentially expressed SE. (Right) Plot of fold change of Pol II loading on
**p% 0.01. See also Figure S7 and Table S4.most dramatic increase in Pol II loading in the absence of
ZMYND8 (Figure 5E; log2FoldChange > 1), with the 30RR
core enhancers hs1,2 and hs3b showing the highest enrich-
ment. We concluded that ZMYND8 deficiency correlates with
increased transcription of B cell super-enhancers.
ZMYND8 Is Required for Efficient SHM of the Igh
Variable Region
The 30RR is also essential for somatic hypermutation of Igh var-
iable region genes (Rouaud et al., 2013). To determine whether
ZMYND8 is required for SHM of the Igh variable regions, we
sequenced the intronic region downstream the JH4 element of
germinal center (GC) B cells from Peyer’s patches of aged
mice (Jolly et al., 1997). As expected, GC B cells from control
mice displayed a high mutation frequency (Figures 6A, 6B,
and 6E), which reflects the chronic nature of the B cell stimula-
tion in Peyer’s patches (Gonza´lez-Ferna´ndez et al., 1994). Nearly
all sequences contained mutations (97%; 92/95), and a consid-
erable portion of clones was heavily mutated (Figures 6A, 6B,
and 6E). In contrast, GC B cells from Zmynd8F/FCD19Cre/+
mice accumulated mutations at a significantly lower rate (Fig-
ures 6A, 6C, and 6E), and the proportion of mutated sequences
was decreased (77%; 94/122). Furthermore, when comparing
the number of mutations per sequence, Zmynd8F/FCD19Cre/+
mice exhibited a skewed distribution with a considerable in-
crease in the number of sequences bearing few mutations and
the nearly complete absence of highly mutated clones (Figures
6A and 6C). We concluded that ZMYND8 ablation in mature
B cells impairs SHM of the Igh locus.
To assess whether ZMYND8 deficiency causes a general
defect in somatic hypermutation, we analyzed SHM of the Igk
locus, which is not controlled by the 30RR. To do so, we moni-
tored the mutation frequency immediately downstream JK5
gene segment (Rouaud et al., 2013). We found a similar number
of mutated sequences in ZMYND8-deficient (78%; 84/108) and
control mice (83%; 88/106). Furthermore, both the distribution
of mutations per sequence and mutation frequency were indis-
tinguishable between the two groups (Figures 6D and 6E).
Thus, ZMYND8 ablation specifically impairs the SHM process
in the heavy-chain locus without affecting the k light-chain locus.
Altogether, these findings indicate that, under physiologic condi-
tions, ZMYND8 is an essential regulator of the 30 Igh super-
enhancer.or 72 hr with LPS and IL-4. (Bottom) Pol II ChIP-seq tracks overlay at regions
ata from three mice per genotype (error bars represent SD). Significance was
ion with LPS and IL-4 (left) or LPS only (right). Two sets of primers amplifying
e 4–6mice per genotype (error bars represent SD). OneCd19Cre/+mousewithin
ated with the Mann-Whitney U test.
as determined by RNA-seq in controls (WT bulk and clonal derivative WTc) and
row-normalized by Z score. Three independent RNA-seq replicates per sample
3b, and hs3a are shown. The adjusted p values were calculated with the Wald
entially expressed in Zmynd8/ versus WT CH12 as measured by RNA-seq.
the differentially expressed super-enhancers defined in the left panel is shown.
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Figure 7. Model for ZMYND8 Function in Igh
Gene Diversification
ZMYND8 controls both CSR and Igh SHM via its
ability to regulate the activity of the 30 Igh super-
enhancer. GTL for S-Cg1 is representative of
acceptor S region induction.DISCUSSION
Despite initially identifying ZMYND8 as an interactor of the DNA
repair factor Rif1, we were unable to document a significant
effect of ZMYND8 in DSB repair in ZMYND8-deficient CH12 or
MEF cells, irrespective of the source of DNA damage. This
observation is consistent with the finding that the interaction be-
tween Rif1 and ZMYND8 in B cells undergoing CSR is not influ-
enced by DNA damage or the ATM kinase. Pol II loading at the
30RR was not altered in Rif1-deficient cells, thus indicating
that, in contrast to ZMYND8, Rif1 does not act as a regulator
of the 30RR. Altogether, these results raise the possibility that
the interaction between Rif1 and ZMYND8 might be accidental.
However, we cannot exclude the intriguing possibility that Rif1
and ZMYND8 also contribute to CSR or other cellular functions
by a common mechanism that is independent of their respective
roles in DNA end protection and 30RR regulation.
Mutation of the 30RR in mice showed that it is necessary to
support CSR and SHM (Cogne´ et al., 1994; Garot et al., 2016;
Le Noir et al., 2017; Manis et al., 1998; Pinaud et al., 2001;
Rouaud et al., 2013; Saintamand et al., 2015b, 2016; Vincent-Fa-
bert et al., 2010). More specifically, the 30RR regulates the early
steps of CSR, including donor and acceptor GLT transcription,
Pol II pausing, AID targeting, and DSB formation; however, it is
dispensable for resolution of CSR breaks and the DSB repair
pathway choice between classical and alternative NHEJ. We
have found that deletion of ZMYND8 increases 30RR-transcrip-
tional activity and phenocopies key aspects of the 30RR
deficiency. Consistent with this idea, ZMYND8 is necessary
to support GLT of acceptor S regions and CSR. Furthermore,Figure 6. ZMYND8 Is Required for Efficient SHM of the Heavy, but Not Light, Ig Chain
(A and D) Cumulative pie charts showing percentage of sequences bearing indicated mutations in 30 JH4 (A
patches B cells of aged unimmunized mice (4 mice per group). Total number of analyzed sequences is indicat
over 510 bp downstream JH4 gene segment and 536 bp downstream JK5 gene segment. GC, germinal cen
(B and C) Distribution of mutations per cloned sequences in individual Cd19Cre/+ (B) and Zmynd8F/FCd19Cre
(E) Summary table listing number of analyzed sequences and total length, number of mutations, andmutation
B cells from (A) and (D). Significance was calculated with the Mann-Whitney U test.
MolecularZMYND8 deficiency impairs SHM specif-
ically at the Igh locus. Given ZMYND8
association with 30RR and its ability to
repress enhancer transcription, these
findings suggest that ZMYND8 is a key
regulator of the 30RR activity in mature
B cells (Figure 7).
The spectrum of phenotypes exhibited
by ZMYND8-deficient B cells and cells
lacking the full 30RR is not entirely over-
lapping. ZMYND8 acts on the accessi-
bility of the acceptor S region ratherthan the donor Sm region. In this regard, the phenotype of
Zmynd8F/FCd19Cre/+ cells is more reminiscent of B cells
harboring deletions or replacements of some portions of the
30RR (Dhs1,2 or D(hs3b-hs4); Cogne´ et al., 1994; Pinaud
et al., 2001), which reduced GLT of several acceptor regions
while leaving donor GLTm unaffected. However, whereas these
partial deletions within the 30RR did not significantly affect g1
GLT and switching to IgG1 (Cogne´ et al., 1994; Manis et al.,
1998; Pinaud et al., 2001), ZMYND8 deficiency considerably
reduced IgG1 CSR, albeit to a lesser extent than the full
30RR deletion (Saintamand et al., 2015b; Vincent-Fabert et al.,
2010). Given the intrinsic differences and degrees of phenotype
penetrance exhibited by various deletions of internal portions of
the 30RR (Be´bin et al., 2010; Cogne´ et al., 1994; Garot et al.,
2016; Le Noir et al., 2017; Manis et al., 1998; Pinaud et al.,
2001; Saintamand et al., 2016; Vincent-Fabert et al., 2009),
and the fact that ZMYND8 is a trans-acting factor that appears
to differentially affect 30RR modules, it is not at all surprising
that ZMYND8 deficiency does not entirely phenocopy the full
30RR deletion.
In plasma cells and resting B cells, the 30RR contacts
regions surrounding the 50 Em enhancer (VDJ-Em), and upon
activation, specific S regions are recruited into the VDJ-30RR
loop in a cytokine-dependent manner (Ju et al., 2007; Wuerffel
et al., 2007). This topological organization is thought to facili-
tate both GLT expression and synapsis of recombining
S regions. 4C analysis with a bait within the 30RR did not
show differences in the profile of long-range chromatin
interactions within the Igh locus, suggesting that ZMYND8
binding to the Igh super-enhancers might not contribute to) and 30 Jk5 (D) regions cloned from sorted Peyer’s
ed below each pie chart. Mutations were quantified
ter; NGC, non-germinal center.
/+ (C) mice.
frequency at JH4 and JK5 introns in germinal center
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the establishment or maintenance of this architectural struc-
ture (data not shown).
Instead, the data support the possibility that ZMYND8 sup-
pression of RNA Pol II loading on the 30RR enhancer favors
GLT transcription by removing local competition for Igh tran-
scription factors. In support of this model, replacement of indi-
vidual (hs1,2 or hs3a) or paired (hs3b and hs4) core enhancers
with an actively transcribed neomycin gene cassette resulted
in a more severe defect in acceptor GLT expression and CSR
than deletion of the same modules (Cogne´ et al., 1994; Manis
et al., 1998; Pinaud et al., 2001). Thus, deregulated transcription
within the 30RR interferes with its activity and disrupts the phys-
iological regulation of GLT and CSR. Our data identify ZMYND8
as a key regulator of 30RR transcriptional activity under physio-
logic circumstances.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Source of cell lines and mouse models used in the study is reported in the Key Resources Table. All experiments were performed in
compliance with EU Directive 2010/63/EU, and in agreement with protocols approved by Landesamt f€ur Gesundheit und Soziales
(LAGeSo, Berlin), The Rockefeller University (NY), and the National Institutes of Health (NIH) Institutional Animal Care and Use
Committees.
METHOD DETAILS
Mice
Rif1FH/FH (Cornacchia et al., 2012), Cd19Cre mice (Rickert et al., 1997), and AID(Aicda)/ (Muramatsu et al., 2000) were previously
described. The conditional Zmynd8F allele bears LoxP sites flanking Exon 4 (ENSMUSE00001273891), and was generated by
crossing the knockout first allele with conditional potential Zmynd8tm1a (European Mouse Mutant Archive, EMMA #05720) with
the ROSA26Flpo deleter strain (The Jackson Laboratory). Germline transmission was confirmed and positive pups were bred with
Cd19Cre mice to generate Zmynd8F/FCd19Cre/+ mice. Mice were maintained in a specific pathogen-free (SPF) barrier facility under
standardized conditions (20+/2C temperature; 55% ± 15% humidity) on a 12 h light/12 h dark cycle. Both male and female
mice were used for the experiments. Primers used for genotyping the Zmynd8F allele are listed in Table S5.
Cell Cultures and Retroviral Infection
B lymphocytes were isolated from mouse spleens using anti-CD43 MicroBeads (Miltenyi Biotec) and stimulated to undergo class
switching with 25 mg/ml LPS (Sigma-Aldrich) and 5 ng/ml of mouse recombinant IL-4 (Sigma-Aldrich) for CSR to IgG1; 25 mg/ml
LPS, 10 ng/ml BAFF (PeproTech) and 2 ng/ml TGFb (R&D Systems) for CSR to IgG2b; or 25 mg/ml LPS only for CSR to IgG3.
Mice 7 to 20 weeks old were used in age-matched groups for splenocytes isolation and CSR assays. CH12 cells (Nakamura
et al., 1996) were stimulated to undergo CSR to IgA by treatment with 5-15 mg/mL aCD40 (BioLegend), 5 ng/ml TGFb and 5 ng/ml
of mouse recombinant IL-4 for 48 h. pMX-ZMYND8-3XFlag retroviral vector was generated by cloning the cDNA for murine ZMYND8
into pMX-IRES-GFP with a C-terminal 3XFlag tag. For CH12 infections with pMX-based retroviral vectors, cells were subjected to
2 rounds of infection with amphotrophic retroviral supernatant, with or without selection with 1 mg/ml of Puromycin (Sigma-Aldrich),
followed by activation for 48 h before analysis for CSR efficiency.
I-DIRT
B cells from Rif1FH/FH and WT mice were isolated and cultured in SILAC medium composed by RPMI (-Arg, -Lys) medium (Thermo
Scientific), L-glutamine, sodium pyruvate, HEPES, 50 mM2-mercaptoethanol, antibiotic/antimitotic, 10%dialyzed fetal bovine serum
(GIBCO), LPS, IL-4 and RP/14 (BD-Biosciences), and supplementedwith either 13C6 L-arginine and
13C6 L-lysine (Cambridge Isotope
Laboratories) (heavy medium; Rif1FH/FH culture), or non-labeled L-arginine and L-lysine (Sigma-Aldrich) (light medium; WT culture).
Cells were cultured in SILAC medium for 96 h to ensure near-complete incorporation of the labeled amino acids. For IR treatment,
cells were exposed to an X-rays source at a rate of 278.2 Rads/min for 431 s (20 Grays), followed by recovery at 37C for 45 min.
Immunoisolation of RIF1FH Complexes
Rif1-containing complexes were extracted in soluble form and immune-isolated after sub-stoichiometric treatment with glutaralde-
hyde in order to stabilize labile interactions without perturbing the native composition of protein complexes. Specifically, 2.6x109 cells
per culture (Rif1FH/FH andWT) were collected by centrifugation, resuspended in 20 mMHEPES containing 1.2% polyvinylpyrrolidone
(Sigma-Aldrich), protease and phosphatase inhibitor cocktails (Roche), 0.5 mM DTT, and frozen in liquid nitrogen. Rif1FH/FH andWTMolecular Cell 72, 636–649.e1–e8, November 15, 2018 e4
frozen cells were mixed in a 1:1 ratio and cryogenically disrupted by wet milling in a Planetary Ball Mill PM 100 (Retsch). The resulting
frozen cell grindate was rapidly thawed in extraction buffer (20mM Tris-Cl pH 8, 150 mM NaCl, 0.5% Igepal CA-630, 1.5 mMMgCl2,
Benzonase, protease and phosphatase inhibitor) supplemented with 2.5 mM Glutaraldehyde (Sigma-Aldrich), and quenched with
100mMTris-CL pH8.0 buffer after 5min incubation. The lysate was clarified by 10min centrifugation at 13,000 rpmat 4C, and imme-
diately incubated with magnetic beads (M-270 epoxy beads, Invitrogen) conjugated with anti-Flag M2 (Sigma-Aldrich) antibody for
1 h at 4C (Di Virgilio et al., 2013). The bead preparationwas thenwashed in extraction buffer, andRIF1FH bait and associated proteins
were eluted twice under native conditions by two rounds of incubation with 2.5 mg/ml 3XFlag peptide (Sigma-Aldrich) for 45min at 4C
with shaking.
Mass Spectrometric Analysis
Rif1 baits and co-purifying proteins were resolved by 4%–12% Bis-Tris gel and visualized by Coomassie blue staining. The gel was
divided into upper and lower parts along the 39kDa molecular weight marker, with only the lower part fixed. The protein-containing
upper and lower parts were cut into 5 and 1 regions respectively, and the gel samples were subjected to in-gel tryptic digestion. Pep-
tides were extracted and purified, analyzed by LCMS using a Thermo Q Exactive Plus mass spectrometer, with a Thermo Easy-nLC
1000 HPLC and a Thermo Easy-Spray electrospray source. Identification and quantification of proteins was performed by searching
against a mouse protein sequence database with the MaxQuant software (version 1.2.2.5) (Cox and Mann, 2008). Protein H/(H+L)
ratios were derived using peptides’ H/L intensity values in MaxQuant output.
CRISPR-Cas9 Gene Targeting
gRNAs for functional screens for loss of CSR function in CH12were cloned into the U6 cassette of pX458 plasmid (pSpCas9(BB)-2A-
GFP, Addgene #48138). For the loss of CSR screen, 3-6 gRNAs per candidate were cloned and tested, either individually or in pools.
CH12 cells were transfected with Cas9-gRNAs expressing constructs via electroporation with Neon Transfection System (Thermo
Fisher Scientific), sorted for GFP-positive cells after 40 h, and left to recover for 72 h before activation for CSR analysis. CH12
and MEFs clonal derivatives were generated via electroporation with either single gRNA and WT Cas9-based plasmid (pX458) or
gRNA pairs and nickase Cas9-based plasmid. In the latter case, tandem U6 cassettes were cloned into a mutated version of
pX458 expressing Cas9D10A. Single GFP-positive cells were sorted in 96-well plates and clones were allowed to grow for 12 days
(CH12) or 17 days (MEFs) days before expansion. Clones were validated at the level of genomic scar and protein expression. The
sequences of the gRNAs employed in these studies are listed in Table S5. The scheme of Zmynd8 genomic locus in Figure 1A is
adapted from Ensembl ENSMUST00000109269.7. Controls for gRNA-nucleofected CH12 bulk cultures were cells nucleofected
either with empty vector or gRNAs against random sequences not present in mouse genome. Controls for CH12 / MEF clonal de-
rivatives included both WT cultures, WT clonal derivatives, and clones derived from targeting CH12 / MEF with random sequences
not present in mouse genome.
Cell Lysates and CoIP Assay
Co-immunoprecipitation analyses were performed as for I-DIRT pull-down with the only exception that protein elution frommagnetic
beads was performed by incubation with NuPage LDS Sample buffer (Thermo Fisher) supplemented with 50mM DTT for 10 min
at 70C. Where indicated, 10 mMATMi KU55933 (Tocris Bioscience) was added 1h before irradiation. Western blot analysis of protein
levels was performed on whole cell lysates prepared by lysis in RIPA buffer supplemented with Complete EDTA free proteinase in-
hibitor (Roche). The antibodies used forWB analysis are: anti-Rif1 (Di Virgilio et al., 2013), anti-FlagM2 (Sigma-Aldrich), anti-ZMYND8
(Sigma-Aldrich), anti-gH2AX (Millipore), anti-b Actin (Sigma-Aldrich), and anti-53BP1 (Bethyl).
Flow Cytometry
For class switching assays, cell suspensions were stained with fluorochrome-conjugated anti-IgG1, anti-IgG3 (BD-Biosciences),
anti-IgG2b (BioLegend), or anti-IgA (Southern Biotech). Samples were acquired on a LSRFortessa cell analyzer (BD-Biosciences).
Analysis of B cell development and differentiation was performed using anti-CD21/CD35-FITC, anti-IgD-FITC, anti-IgM-PE, anti-
IgM-FITC, anti-CD43-PE (BD-Biosciences) and anti-CD23-PE, anti-CD3-PE and anti-CD19-APC (BioLegend) antibodies. For cell
proliferation analysis by cell tracking dye dilution, primary B cells were pulsed with 2 mM carboxyfluorescein succinimidyl ester
(CFSE) (Invitrogen) or 5 mM CellTrace Violet (Thermofisher) for 10 min at 37C. CFSE/CellTrace covalently labels intracellular mole-
cules, and each cell division halves the signal intensity. For cell cycle analysis, CH12 cells were collected, fixed, and permeabilized
using Fixation/Permeabilization Solution (included in BrdU Flow Kit, BD-Biosciences) according to the manufacturer’s instructions.
BrdU pulse and staining was performed by using BrdU Flow Kit (BD-Biosciences) according to the manufacturer’s instructions.
Mice Immunization and Ig Serum Titers
For T cell-dependent immunization, 9 to 18 week old mice were injected intraperitoneally with 100 mg alum (Sigma-Aldrich)-precip-
itated NP-CGG16 (Biosearch Technologies). Blood was collected before and at day 7 and 20 after immunization. Serum specific IgM
and IgG1 antibodies against NP hapten were determined by ELISA. NP-IgM and NP-IgG1 preparations for standard curves were a
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Quantitative PCR
mRNA levels for AID, pre- and post-spliced germline transcripts, and 30RR hs eRNA levels were measured as it follows. Total RNA
was extracted from splenocytes cultures 48 h after activation using TRIzol (Invitrogen) or RNeasy Mini Kit (QIAGEN) according to
manufacturer’s instructions, and retro-transcribed with SuperScript VILO cDNA Synthesis Kit (Invitrogen). When using TRIzol,
genomic DNA was removed by RapidOut DNA Removal Kit (Thermo Scientific). Transcripts were amplified using StepOnePlus
Real-Time PCR System (Applied Biosystems) with Luna Universal qPCR Mastermix (NEB). Primers used for qPCR (this paper; Mur-
amatsu et al., 2000; Oruc et al., 2007; Xu et al., 2015) are listed in Table S5.
Immunofluorescence
iMEFswere grown on coverslips overnight. Cells were irradiated (10Gy IR) and allowed to recover for 90min or 6 h. Upon fixation with
4% paraformaldehyde (Sigma-Aldrich) and permeabilization with 0.5% Triton X-100, cells were stained with anti-gH2AX (Millipore),
rabbit anti-Rif1 serum (Di Virgilio et al., 2013), mouse anti-53BP1 (Millipore), mouse anti-Flag M2 (Sigma-Aldrich) or rabbit anti-
ZMYND8 (Sigma-Aldrich) antibodies as primary antibodies, and with goat anti-rabbit Alexa546 and goat anti-mouse Alexa488 (Invi-
trogen) as secondary antibodies. Images were acquired using inverted LSM700 laser scanning confocal microscope (Zeiss).
Clonogenic Assay
For the colony formation assay following IR, iMEFs were plated in 60mm dishes, irradiated after 24 hr with the indicated doses and
incubated at 37C in the presence of 5% CO2. After 14 days, colonies were fixed with 15% acetic acid: methanol (v/v) for 5 min and
stained with 0.5%Crystal Violet (Sigma-Aldrich) for 30 min for colony visualization. For the colony formation assay in the presence of
PARPi (Olaparib/AZD2281, Selleckchem), 0.1, 1, and 5 mM PARPi was added 24 after seeding and cells allowed to grow for 14 days
before fixation, with fresh media and PARPi replenished on day 7.
Metaphase Analysis
iMEFs were treated with 2 mM PARPi for 21 h followed by 1 h incubation at 37C with Colcemid (Sigma-Aldrich). Metaphase prep-
aration and aberration analysis were performed as it follows. Cell pellets were resuspended in 0.075M KCl at 37C for 20 min to
perform a hypotonic shock, and washed/fixed with methanol/glacial-acetic acid solution. Metaphase spreads were prepared by
dropping fixed cells on microscope slides, which were air-dried and placed at 42C for 1 h. Giemsa staining was performed by using
KaryoMAX Giemsa Stain Solution and Gurr Buffer Tablets (GIBCO). Metaphases were acquired with the Automated Metaphase
Finder System Metafer4 (MetaSystems).
End Resection Assay
Single guide RNAs targeting two sequences 2276 bp apart within the ROSA26 locus were cloned into pX458 plasmid (gDSB-1/2).
CH12 cells were electroporated with a 1:1 mix of gDSB-1 and gDSB-2 constructs using the Neon Transfection System (Thermo
Fisher Scientific), and allowed to recover for 24 h before collection. Genomic DNA was extracted according to standard protocols
and individual repair junctions were amplified using nested PCR reactions. PCR products were extracted from agarose gel and
sequenced. Single guide RNAs and primers used for the end resection assay are listed in Table S5.
CRISPR-Cas9-Induced CSR Assay
Constructs for expression of gRNA-Sm and gRNA-Sa were generated by cloning single guide RNAs directed to the 50 Sm and 30 Sa
regions respectively of the Igh locus (Ramachandran et al., 2016) in tandem U6 cassettes on a modified pX458 plasmid backbone.
Control construct was generated by cloning random sequences not targeting the mouse genome in tandem U6 cassettes on same
plasmid. CH12 cells were electroporated with the constructs using the Neon Transfection System, and allowed to recover for 12 h
before CSR analysis.
MutPE-Seq
Primary cultures of splenocytes were collected at either 72 h or 96 h post-activation. gDNA was extracted with phenol-chlorofom-
isoamyl alcohol, and 50 Sm amplicon was amplified and prepared for deep-sequencing by two rounds of PCR. The first round of PCR
amplification was performed with Phusion High-Fidelity DNA Polymerase (Thermo Scientific) (annealing temperature of 64.9C, 15,’’
20 cycles) and locus-specific primers for 50 Switch m. Two/thirds of DNA from the first reaction was used as template for the second
reaction (annealing temperature of 64.6C, 15,’’ 15 cycles) to introduce sequencing adapters and genotype-specific barcodes. Gel-
extracted amplicons were pooled and sequenced via 2 3 300bp Paired-end Read Sequencing on an Illumina MiSeq platform. Mu-
tations present in only one of the paired reads were considered a sequencing artifact and discarded. Primers used for MutPE-Seq
(Wang et al., 2017) are listed in Table S5.
ChIP-Seq
ChIP-seq for ZMYND8 and RNA Pol II were performed as it follows. Splenocytes (72 h post-activation) or CH12 cells (48 h post-acti-
vation) were fixed with 1% (16% Formaldehyde Methanol-free, Thermo Scientific) at 37C for 10 min followed by addition of 1/20
volume of 2.5 M glycine (dissolved in PBS pH 7.4) and swirling. Fixed cells were washed with cold PBS,centrifuged and aliquoted.Molecular Cell 72, 636–649.e1–e8, November 15, 2018 e6
20 million cells were resuspended in 100 mL of 1% SDS of RIPA buffer supplemented with Complete EDTA free proteinase inhibitor
(Roche) and sonication was performed with a Covaris S220 Focused Ultrasonicator at peak value 105, duty factor 5, cycle/burst 200
for 10min. After sonication, samples were adjusted to 0.1%SDS final concentration by diluting with non-SDS containing RIPA buffer.
Chromatin fragments were then pre-cleaned by incubation with Dynabeads Protein A (Invitrogen) with rotation at 4C for 1 h, and
immunoprecipitated with antibody-bound Dynabeads. 10 ug antibodies specific for ZMYND8 (Sigma-Aldrich) or RNA Pol II polymer-
ase (4H8, Abcam) were used for each sample. DNA libraries were prepared by using Illumina compatible adaptors (Bio Scientific) and
sequenced on an Illumina NextSeq 500 Sequencer. FASTQ files were aligned against mouse genome (mm10) using BWA mem
(Li and Durbin, 2009). Processing and peak-calling of ChIP-seq data were accomplished with HOMER ChIP-Seq program (Heinz
et al., 2010). Peak annotation was done using R and ChIPseeker package (Yu et al., 2015). The schematic representation of the mu-
rine Igh locus in Figures 4C, 5A, and S7A encompasses nucleotides 113,175,000-113,441,797 on Chr12.
RNA-Seq
Samples used in RNA-seq were cultured in activated and unactivated conditions for 48 h. Cultured cells were collected by centrifu-
gation and RNA was extracted with AllPrep DNA/RNA Mini Kit (QIAGEN). Ribosomal RNA was depleted using Ribo-Zero Gold rRNA
Removal Kit (Illumina). Libraries were prepared with TruSeq Stranded Total RNA Library Prep Kit (Illumina). Three biological repeats
were performed and run in two lanes on the same flow cells on NextSeq High Output 75 SR (Illumina). For data analysis, reads were
pseudo-aligned to an index created from the Ensembl mouse GRCm38.p5 assembly and custom annotations of Igh locus features.
Transcript-level abundances were quantified using kallisto v0.43.0 (Bray et al., 2016), and subsequently summarized to the gene-
level using the R package tximport (Soneson et al., 2015). Differential gene expression analysis was performed using DESeq2
(Love et al., 2014).
GRO-Seq
The GRO-Seq analysis was performed on splenocytes 24 h after stimulation with LPS and IL-4 as it follows. Global run-on and library
preparation for sequencing was performed on nuclei from 10-15 million cells. After run-on reaction, the RNA was extracted with
TRIzol LS Reagent (Invitrogen). RNA was treated with TURBO DNase (Invitrogen), fragmented using RNA Fragmentation Reagents
(Invitrogen) and purified by running through BioSpin P-30 Gel Columns (Bio-Rad). The 30 end of the fragmented RNA was dephos-
phorylated with T4 Polynucleotide Kinase (NEB) followed by heat-inactivation. Dephosphorylation reactions were purified using anti-
BrdU beads (Santa Cruz Biotech) and precipitated overnight. Poly(A)-tailing and cDNA synthesis were performed the next day. For
reverse transcription, an oligo allowing custom barcoding during final amplification was used (RT-primer).
After cDNA synthesis, Exonuclease I (NEB) was used to catalyze the removal of excess oligo. The DNA–RNA hybrid was purified
using ChIP DNAClean &Concentrator Kit (ZymoResearch Corporation), RNase H (Thermo Scientific) treated and circularized. Circu-
larized cDNAs were relinearized using APE1 (NEB) and were amplified for 12–14 cycles with primers oNTI201 and oNTI200. The final
product was ran on a gel, purified, and cleaned up as above. DNA libraries were sequenced on a Hi-Seq 2500 for 50 cycle, single end
run and the standard pipeline (1.8.2) was used for image analysis and base calling. Reads were aligned to the National Center for
Biotechnology Information mouse genome data (July 2007; NCBI37/mm9) by using the alignment software Bowtie (Langmead
et al., 2009) with the following options: -S –m 1 –p [num_of_thread] -a–best–starta –n 2 –l [read_length] –trim5 2. These options report
reads that align uniquely to the best stratum and allowing up to 2 mismatches after trimming 2 nucleotides from the 50 end. For visu-
alization, stranded density tracks were generated by using bedtools genomecov programwith a normalizing scale factor to calculate
rpm separately for each strand. Rpkm valuewas calculated for comparative analysis and one sample t.test in R packagewas used for
the p values. Primers used for GRO-Seq (Ingolia et al., 2009) are listed in Table S5.
Switch Junction Analysis
Genomic DNA was extracted from splenocytes stimulated for 96 h with LPS and IL-4, and Sm-Sg1 junctions were amplified by two
rounds of PCR using Phusion High-Fidelity DNA Polymerase (Thermo Scientific). PCR annealing conditions were 72C, 20 and 10
cycles for the first round and 72C, 20 and 20 cycles for the second round. PCR products were run on agarose gels, and fragments
corresponding to 350-1000 bp were extracted with NucleoSpin DNA Purification Kit (Macherey-Nagel), cloned using TOPO-TA clon-
ing kit (Invitrogen) and sequenced using M13 forward and reverse universal primers. Primers used for Switch junction analysis
(Di Virgilio et al., 2013) are listed in Table S5.
SHM Analysis
Single-cell suspensions from Peyer’s patches of 30-31 weeks old mice were first incubated with anti-mouse CD16/32 (BioLegend)
and then labeled with B220-FITC– (BioLegend), CD19-APC– (BioLegend), CD38-Alexa700– (Thermo Scientific), and CD95/Fas-PE–
(BD-Biosciences) conjugated antibodies. Non-germinal center (CD38+ Fas) and germinal center B cells (CD38 Fas+) were sorted
on an Aria BD sorter. Genomic DNA was extracted and the 50 portions of JH4 (Igh) and JK5 (Igk) introns were amplified by PCR using
Phusion High-Fidelity DNA Polymerase (Thermo Scientific). The 800 bp JH4 and 700 bp JK5 PCR products were gel extracted, cloned
into a pCR2.1 vector using the TOPO TACloning Kit (Invitrogen) and sequenced. Mutations were quantified over 510 bp downstream
JH4 and 536 bp downstream JK5 gene segments. Primers used for SHManalysis (Rouaud et al., 2013; Sander et al., 2015) are listed in
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QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical significance of differences between groups/datasets was determined by the Mann–Whitney U test for all data pre-
sented in this study, with the following exceptions. The significance for the quantification of RNA Pol II ChIP-seq data (Figure 5B)
was calculated with the Welch 2 sample unpaired t test. The adjusted p values for the quantification of relative transcript levels at
hs4, hs1,2, hs3b, hs3a (Figure 5D) were calculatedwith theWald test, and corrected formultiple-testing with the Benjamini-Hochberg
method. ** is q < 1x10^-7 for hs1,2 and q < 1x10^-9 for hs3b. The pvalues for the differential gene analysis of GRO-Seq data (Fig-
ure S5E) were calculated with one-sided one sample t.test (mu = 0) on log2FC. Statistical details of experiments can be found in the
figure legends.
DATA AND SOFTWARE AVAILABILITY
The accession number for the deep-sequencing data reported in this paper (ChIP-seq, RNA-seq, and GRO-seq) is GEO:
GSE118794. Original imaging and western blot data used to generate any of the figure panels have been deposited at Mendeley:
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